https://docetaxelinhibitor.com..../losing-gentle-on-mo
Three metabolic enzymes, dihydropyrimidine dehydrogenase (DPD), dihydropyrimidinase (DHP), and β-ureidopropionase (β-UP), degrade FPs; thus, deficiencies in these enzymes, arising from hereditary polymorphisms, are involved in severe FP-related toxicity, even though the aftereffect of these polymorphisms on in vivo enzymatic task is not clarified. Additionally, the clinical usefulness of present means of predicting in vivo activity, such pyrimidine levels in blood or urine, is unknown. In vit
Like
Comment
Share
